With 20 blockbuster launches, Novartis CEO Narasimhan hopes to overcome a $9 billion patent cliff.
Summary- Leading the charge for Narasimhan’s blockbuster launch list is cholesterol therapy Leqvio, which awaits an FDA decision on Jan. 1. Others…
Summary- Leading the charge for Narasimhan’s blockbuster launch list is cholesterol therapy Leqvio, which awaits an FDA decision on Jan. 1. Others…
Abstract: The European Commission has approved Pfizer`s first-of-its-kind oral Janus kinase (JAK) inhibitor XELJANZ® (Tofacitinib) 5 mg twice daily for the treatment…
SYNOPSIS: GlaxoSmithKline Plc released positive trial results for a potential blockbuster anemia pill the company is hoping will bolster its pharma portfolio…
Abstract: The National Institute for Health and Care Excellence (NICE) has issued an Appraisal Consultation Document (ACD) for AstraZeneca’s Forxiga (Dapagliflozin) within…
KEYPOINTS: Australia’s medicines and medical devices regulator on Monday formally recognised India’s Covaxin, a vaccine against the coronavirus as the country’s border…
Novartis says that the U.S. and European regulators have accepted its marketing applications for CAR-T cell therapy Kymriah (Tisagenlecleucel) as third-line therapy…
Summary- BioNTech in bid to build manufacturing expertise in Africa Project seeks to avoid repeat of COVID-19 vaccine inequality Backed by EU…
The European Commission has cleared Keytruda (Pembrolizumab) in combination with chemotherapy as a first-line treatment for locally recurrent, unresectable or metastatic TNBC…
Keypoints UPL is the largest manufacturer and distributor of biosolutions worldwide. On 28 June 2021 UPL Ltd, a world leader in sustainable…
Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced that the clinical trial of…